全文获取类型
收费全文 | 21365篇 |
免费 | 1521篇 |
国内免费 | 194篇 |
专业分类
耳鼻咽喉 | 356篇 |
儿科学 | 426篇 |
妇产科学 | 437篇 |
基础医学 | 2803篇 |
口腔科学 | 545篇 |
临床医学 | 1981篇 |
内科学 | 4399篇 |
皮肤病学 | 611篇 |
神经病学 | 1376篇 |
特种医学 | 1271篇 |
外科学 | 2797篇 |
综合类 | 762篇 |
一般理论 | 14篇 |
预防医学 | 1064篇 |
眼科学 | 723篇 |
药学 | 1641篇 |
1篇 | |
中国医学 | 172篇 |
肿瘤学 | 1701篇 |
出版年
2023年 | 175篇 |
2022年 | 84篇 |
2021年 | 589篇 |
2020年 | 450篇 |
2019年 | 547篇 |
2018年 | 723篇 |
2017年 | 529篇 |
2016年 | 636篇 |
2015年 | 843篇 |
2014年 | 1040篇 |
2013年 | 1117篇 |
2012年 | 1721篇 |
2011年 | 1684篇 |
2010年 | 970篇 |
2009年 | 901篇 |
2008年 | 1198篇 |
2007年 | 1192篇 |
2006年 | 1139篇 |
2005年 | 1085篇 |
2004年 | 850篇 |
2003年 | 701篇 |
2002年 | 575篇 |
2001年 | 543篇 |
2000年 | 524篇 |
1999年 | 421篇 |
1998年 | 192篇 |
1997年 | 176篇 |
1996年 | 130篇 |
1995年 | 137篇 |
1994年 | 119篇 |
1993年 | 107篇 |
1992年 | 168篇 |
1991年 | 176篇 |
1990年 | 149篇 |
1989年 | 155篇 |
1988年 | 138篇 |
1987年 | 160篇 |
1986年 | 120篇 |
1985年 | 111篇 |
1984年 | 83篇 |
1983年 | 81篇 |
1982年 | 46篇 |
1980年 | 41篇 |
1979年 | 61篇 |
1977年 | 50篇 |
1975年 | 40篇 |
1974年 | 39篇 |
1973年 | 37篇 |
1972年 | 38篇 |
1969年 | 41篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
Francesco Esposito Chetana Lim Eylon Lahat Chaya Shwaartz Rony Eshkenazy Chady Salloum Daniel Azoulay 《HPB : the official journal of the International Hepato Pancreato Biliary Association》2019,21(9):1099-1106
BackgroundSome patients remain deemed unsuitable for resection after portal vein embolization (PVE) because of insufficient hypertrophy of the future remnant liver (FRL). Hepatic and portal vein embolization (HPVE) has been shown to induce hypertrophy of the FRL. The aim of this study was to provide a systematic review of the available literature on HPVE as preparation for major hepatectomy.MethodsThe literature search was performed on online databases. Studies including patients who underwent preoperative HPVE were retrieved for evaluation.ResultsSix articles including 68 patients were published between 2003 and 2017. HPVE was performed successfully in all patients with no mortality and morbidity-related procedures. The degree of hypertrophy of the FRL after HPVE ranged from 33% to 63.3%. Surgical resection after preoperative HPVE could be performed in 85.3% of patients, but 14.7% remained unsuitable for resection because of insufficient hypertrophy of the FRL or tumor progression. Posthepatectomy morbidity and mortality rates were 10.3% and 5.1%, respectively. The postoperative liver failure rate was nil.ConclusionHPVE as a preparation for major hepatectomy appears to be feasible and safe and could increase the resectability of patients initially deemed unsuitable for resection because of absent or insufficient hypertrophy of the FRL after PVE alone. 相似文献
6.
Caryn Wujanto Jeremy Tey David Chia Francis Ho Kiat Huat Ooi Alvin S. Wong Yu Yang Soon Keith Lim 《Journal of Geriatric Oncology》2019,10(2):292-297
Background
Muscle invasive bladder cancer (MIBC) is prevalent in the older patients, who are a vulnerable population with multiple co-morbidities and at increased risk of complications. Radical cystectomy is often not suitable, hence radical radiotherapy (RT) is an alternative option. We reviewed the outcomes of older patients treated with RT with or without concurrent chemotherapy (CRT) at our institution.Methods
We retrospectively reviewed patients aged 65?years and above treated with radical RT for MIBC at our institution between March 2002 to January 2017. Data was collected from institutional medical records and RT databases. The primary outcome was 2- and 5-year overall survival (OS), recurrence free survival (RFS), and toxicities. Univariate cox proportional hazard regression models were performed to identify independent factors with significant impact on survival.Results
We identified 45 patients (34 males, 11 females) with a median age of 77?years (range 65–95). All patients received maximal transurethral resection of the bladder tumour prior to RT. Median dose of total RT was 64?Gy (range 50–69.8?Gy). Twenty one patients (47%) received CRT. Planned treatment was completed in 42 (93.3%) patients. Median follow-up was 31?months (range 1–147?months). The 2- and 5-year OS was 64% and 44%, respectively. The 2- and 5-year RFS was 68% and 49%, respectively. Median RFS was 34?months (range 8–121?months). Median OS was 56?months (range 18–100?months). Univariate analysis showed that performance status (0–1 vs. 2–3; HR 2.7, 95% CI 1.07–6.8, p?=?0.035) and International Society of Geriatric Oncology (SIOG) group (≤2 vs. >2; HR 3.23, 95% CI 1.12–8.64, p?=?0.019) were significantly associated with increased hazard for death. One patient (2%) had grade 3 cystitis.Conclusion
Radical RT is well tolerated in older patients with MIBC. We report outcomes similar to published data. Older patients should be considered for curative treatment despite their age. However, careful selection is warranted as frail patients (PS ≥2; SIOG >2) may benefit less. 相似文献7.
Haider Sameah A. Lim Seokchun Kalkanis Steven N. Lee Ian Y. 《Journal of neuro-oncology》2019,141(3):507-515
Journal of Neuro-Oncology - Glioma surgery at its nascency relied predominantly on visual and tactile feedback for the removal of grossly abnormal tissue. This technique has inherent limitations in... 相似文献
8.
9.
10.
Yasmine Abouleila Kaoru Onidani Ahmed Ali Hirokazu Shoji Takayuki Kawai Chwee Teck Lim Vipin Kumar Shinobu Okaya Ken Kato Eiso Hiyama Toshio Yanagida Tsutomu Masujima Yoshihiro Shimizu Kazufumi Honda 《Cancer science》2019,110(2):697-706
Recently, there has been increased attention on the analysis of circulating tumor cells (CTCs), also known as liquid biopsy, owing to its potential benefits in cancer diagnosis and treatment. Circulating tumor cells are released from primary tumor lesions into the blood stream and eventually metastasize to distant body organs. However, a major hurdle with CTC analysis is their natural scarcity. Existing methods lack sensitivity, specificity, or reproducibility required in CTC characterization and detection. Here, we report untargeted molecular profiling of single CTCs obtained from gastric cancer and colorectal cancer patients, using live single cell mass spectrometry integrated with microfluidics‐based cell enrichment techniques. Using this approach, we showed the difference in the metabolomic profile between CTCs originating from different cancer groups. Moreover, potential biomarkers were putatively annotated to be specific to each cancer type. 相似文献